Our Business.

Since 2018, our experts have designed and manufactured pumpless neuro-organs on chips devices and models with a user-centric experience for a fast adoption of alternative methods in the regulatory approved process.

Our Business

• Consumables
• Services
• Software

What is microfluidics?

• Manipulating fluids
• Micrometric scale
• Economies of scale

What are organs-on-chip?

• Microphysiological systems
• Recapitulate organs functions
• Upcoming alternative method

Our approach - UX

• Democratization of OoCs
• High throughout & high relevance
• Standardize datasets (larger, faster & predictive)


Our Business.

We provide neuro-organs-on-chip & interoperable in vitro models to bridge the gap between
in vitro lab discovery and in vivo human biology

Our goal is to democratize the use of organs-on-chip in order to facilitate their adoption by regulators bodies and healthcare industries. We focus on building partnerships that go beyond commercial alliances and provide innovative combined solutions to our industrial partners.

What is microfluidics?

Microfluidics is both the science of manipulating fluids at the micrometer scale (on the order of a thousandth of a millimeter), and the technology of manufacturing miniaturized devices containing chambers and tunnels through which fluids can either flow or be confined.

Microfluidics allows for economies of scale, particularly in terms of the quantity of products used (smaller quantities), the time spent on experiments (faster) and the total cost of the research project (lower cost).  

What are organs-on-chip?

Organs-on-chips (OoCs), also known as microphysiological systems (MPS) or “tissue chips”, are microfluidic devices containing living cells and aiming at recapitulating various functions of organs. OoCs enable a precise control of the cellular microenvironment to recreate tissue specific functions, whether they be healthy or modelling a pathology. By using human cells, OoCs mimic various key aspects of human physiology, and thus are considered as an upcoming alternative method to animal testing as well as the potential future gold standard to investigate human pathophysiology and future therapeutics. Convinced by their potential benefits, the FDA is now inviting drug developers to include non-animal methods, and especially OoCs, in clinical trial authorization submissions. Some governments are even starting to remove the historical legislative roadblocks, such as the USA with the signature of the Modernization Act 2.0 in 2022.

In this rapidly evolving context, NETRI’s OoCs are tools for drug developers to de-risk their preclinical and clinical investments and provide critical elements to improve their narrative when submitting for clinical trial authorization.

Our approach.

To address this, we believe the future of drug development will be about larger, faster and more predictive datasets.

Contact us

Select your region for the appointment


Discover our new exclusive package
organs-on-chip kits and all our
neuro-organs-on-chip devices.



Quickly and easily adopt organs-on-chip

into users’ research